Etoricoxib is a new COX-2 selective inhibitor and belongs to the group of so-called NSAIDs (Non Steroidal Anti Inflammatory Drugs). Indications are: Treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain, and gout. Etoricoxib is available by prescription only.
Effect
Pharmacodynamics
Etoricoxib is a new COX-2 selective inhibitor. The enzyme cyclooxygenase is significantly involved in inflammatory processes and in the development of pain. Etoricoxib selectively inhibits the isoenzyme COX-2.
Pharmacokinetics
Bioavailability is 100% after oral administration. Plasma protein binding is approximately 92 %. Elimination is hepatic, mainly via the enzyme CYP3A4. The half-life is about 22 hours.
Toxicity
Side effects
Possible adverse effects:
Increase or decrease in blood pressure
back pain
edema (ankles, legs)
Numbness
GIT: stomach pain, flatulence
Decrease in glomerular filtration rate, oliguria
Blood clotting disorders, anemia
Sore throat
Itching
In addition, there is an increased risk of thromboembolic events with the use of coxiben due to selective inhibition of COX-2. Therefore, use is contraindicated in cardiovascular risk patients.
All information used for the content comes from verified sources (recognised institutions, experts, studies by renowned universities). We attach great importance to the qualification of the authors and the scientific background of the information. Thus, we ensure that our research is based on scientific findings.
Markus Falkenstätter, BSc Author
Markus Falkenstätter is a writer on pharmaceutical topics in Medikamio's medical editorial team. He is in the last semester of his pharmacy studies at the University of Vienna and loves scientific work in the field of natural sciences.
Mag. pharm. Stefanie Lehenauer Lector
Stefanie Lehenauer has been a freelance writer for Medikamio since 2020 and studied pharmacy at the University of Vienna. She works as a pharmacist in Vienna and her passion is herbal medicines and their effects.
The content of this page is an automated and high-quality translation from DeepL. You can find the original content in German here.